Catalent’s sweeping workforce reductions within its Maryland gene therapy manufacturing operations were preceded by two FDA inspections in April that resulted in red flags from the agency, FDA fili | ...
Solid Biosciences Inc. (NASDAQ:SLDB) develops therapies for neuromuscular and cardiac diseases in the US. In addition, the ...
An 8-year-old boy made medical history thanks to Columbus doctors. Yet the city where it happened barely registered. Time we ...
Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025. He was an easy selection, but unlike some ...
A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...
A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.
Average Upside Potential as of December 10: 104.08% ...
Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...
The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results